Technology

While patient support providers play an important role in keeping patients on therapy, biopharma companies have a great opportunity to push analytical sophistication beyond what many of these providers currently offer.

Ferdi Steinmann looks at pharma's current relationship with AI and how it is set to evolve.

How technology can maximize use of manufacturer copay and patient assistance programs.

Todd Nichols, chief commercial officer of Alkermes, gives his top three recommendations for going all-in to digitally transform the frontline sales team.

The COVID-19 pandemic has shifted the adoption of digital platforms in pharma and has made the industry reconsider which technologies can improve global health moving forward.

Whether your company already has a data-driven compliance program in place or is contemplating building one, Michael O'Connor and Isha Arora outline four things the DOJ is now focused on that your compliance team needs to know.

Following her own experience, a health tech entrepreneur turned to AI to better guide other patients through their treatment journeys.

Implementing an efficient means of unifying disparate data and allowing teams to utilize this single source of truth data will allow them to track KPIs more effectively and get key insights when they need them.

Companies recognize that their success with digital starts with accurate customer data, but many struggle to manage the overwhelming volume of different data types from hundreds of sources.

Following the introduction this week MyVeeva for Doctors, Veeva’s Paul Shawah discusses the background to the product and the role biopharma companies will play in its ongoing development.

Digital engagement is becoming the new normal, but it can inhibit the individual connection that is foundational to building long-term customer relationships. How can reps, brand teams, and medical science liaisons strike the right balance of personal and non-personal engagement? The next generation of AI has an answer, writes Derek Choy.

Pharma marketers can use their "voice" to increase prominence in advertising.

Lise Stevens explores what difference the ISO IDMP (Identification of Medicinal Products) data standards would have made in a COVID-19 context — in applications ranging from pharmacovigilance adverse event reporting and electronic prescribing to falsified medicines control.

The Medical Affairs Digital Strategy Council's Mary Alice Dwyer and Indegene's Sameer Lal talk to Pharm Exec about how digital solutions can help the Medical Affairs function take a leadership role 
in ensuring fast, efficient, and meaningful responses to all stakeholders at a time of intense pressure.

Report sets out self-assessment measures for low- and middle-income countries in their adoption of new health technologies.

Technology has potential to change how physicians work with asthma patients

A look at how UCB is utilizing dynamic targeting via AI to improve overall patient experience.

Pharma companies are struggling to maintain a high level of cybersecurity amidst the pandemic.

As we wait for a COVID-19 vaccine, pharma is looking to blockchain technology to prepare for the major supply-chain obstacles to come.

Peter Kohut analyses the findings of a survey on how life sciences companies are capitalizing on opportunities to transform workload and data quality management using the latest smart technology.

The recent merger of Teledoc and Livongo into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time?

EXUMA Biotech's Dr. Greg Frost talks about his work making CAR-T cell therapy readily accessible and affordable.

Their application for security and anti-counterfeiting purposes continues to evolve, especially in combination with digital technology.

When approached correctly, drug development in the rare disease space can be quite successful – especially when powerhouses across the industry join forces and leverage the power of data to help drive potential treatment options.

How companies are leveraging Real Word Evidence to evaluate therapies under real world conditions in a broader population at a lower cost than using Randomized Clinical Trials.